Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

The present invention relates to a prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome, the agent containing an mPGES-1 inhibitor as an active ingredient.

The present invention relates to desmethylanethole trithione (AOX) and derivatives thereof, especially derivatives of formula (I), for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin, ##STR00001##

The present invention relates to desmethylanethole trithione (AOX) and derivatives thereof, especially derivatives of formula (I), for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin, ##STR00001##

Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.

A method of treating disorders associated with NO/SNO deficiency or benefiting from increased SNO in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, SNO-CoAR inhibitor, and/or SNO-CoA at an amount(s) effective to promote S-nitrosylation of proteins in the subject.

A method of treating disorders associated with NO/SNO deficiency or benefiting from increased SNO in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, SNO-CoAR inhibitor, and/or SNO-CoA at an amount(s) effective to promote S-nitrosylation of proteins in the subject.

A method of treating disorders associated with NO/SNO deficiency or benefiting from increased SNO in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, SNO-CoAR inhibitor, and/or SNO-CoA at an amount(s) effective to promote S-nitrosylation of proteins in the subject.

The disclosure relates to methods for treating cancers (e.g., cancers having a BRCA1 and/or BRCA2 mutation(s)) by administering to the subject an effective amount of a ubiquitin-specific protease 1 (USP1) inhibitor.